Vaccinia virus MVA-E3L-knockout-mutants and use thereof
AssigneeGSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
InventorsVolker Erfle, Simone Hornemann, Gerd Sutter
Life of this patent
Estimating the term…
Abstract
The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.
Claims23
MVA-knock-out-mutant, wherein the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.
A method for generating a recombinant MVA, the method comprising:
- (a) infecting a host cell with an MVA, wherein an MVA ORF 050L gene or a functional part thereof has been inactivated in the MVA;
- (b) transfecting the host cell with a DNA-vector construct comprising an MVA ORF 050L gene or encoding a functionally equivalent MVA ORF 050L derived polypeptide;
- and
- (c) selecting restored MVA by growth on CEF cells or chicken embryo derived LSCC-H32 cells or avian cells, thereby generating a recombinant MVA.
Dependencies are inferred from the claim text.